Form 4: DexCom Director Nicholas Augustinos Receives Stock Award

Nicholas Augustinos, a director at DexCom Inc., received 2,618 shares of common stock on May 22, 2024, as part of a restricted stock unit (RSU) award.

Summary

• On May 22, 2024, Nicholas Augustinos, a director of DexCom Inc., acquired 2,618 shares of DexCom common stock.
• This acquisition was part of a restricted stock unit (RSU) award.
• The RSU award will vest on the earlier of May 22, 2025, or the date of DexCom's 2025 Annual Meeting of Stockholders.
• Following the transaction, Augustinos directly owns 2,618 shares and indirectly owns 37,083 shares through a trust.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects standard executive compensation practices and aligns director interests with shareholders.

Positives

• The RSU award aligns the director's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment to DexCom's success.

Future Outlook

The document does not contain any specific forward-looking statements regarding DexCom's future performance.

Industry Context

Stock awards are a common form of executive compensation in the technology and healthcare industries, aligning management's interests with shareholder value.

Comparison to Industry Standards

• Stock awards are a typical component of executive compensation packages in the medical device industry, similar to companies like Medtronic and Abbott.
• The vesting schedule of one year is fairly standard for RSU grants.

Stakeholder Impact

• Shareholders may view the RSU award positively as it incentivizes the director to work towards increasing shareholder value.

Key Dates